BEIJING – December 27, 2018 – Novozymes filed in Beijing Intellectual Property Court a lawsuit against Shandong Longda Bio-Products Co., Ltd. (Longda) and its subsidiary Shandong Lonct Enzymes Co., Ltd. (Lonct) after having found that Longda and Lonct continue to infringe Novozymes’ patent.
The patent dispute began in 2011, when Novozymes found evidence that Longda and Jiangsu Boli Bioproducts Co., Ltd. (Boli) were infringing one of Novozymes’ Chinese patents by producing and selling a proprietary Novozymes glucoamylase enzyme for use in the starch, bioenergy and beverage industries.
In 2012 and 2013, two courts in Tianjin ordered Longda and Boli to stop making and selling the products. Longda and Boli appealed, arguing that the patent was invalid. The case passed through several levels of lower courts, before it reached the Supreme People’s Court of China in 2016, which decided that the patent is valid.
“It is highly disappointing that Longda continues to sell the infringing glucoamylase products despite the court’s ruling for them to stop infringing our patent. Proper protection and respect of intellectual property is key to bringing innovation to the market. In this respect, Novozymes appreciates the great efforts and progress made by China in improving the legal framework of protecting intellectual property. We have faith in the Chinese judicial system, and will continue to use it when our intellectual property rights are infringed,” says Novozymes’ Regional President Asia Pacific Sara Dai.
Novozymes invests millions of dollars and years of R&D efforts to develop new products. The company continuously innovates to ensure that its product portfolio contains the latest concepts and applications for a wide range of industries. For example, low-pH amylase is helping the starch processing industry in converting starch into glucose at the lowest possible total cost; another game-changing liquefaction solution has enabled biofuel producers to greatly improve plant efficiency and profitability. Novozymes continues to bring novel cellulase products to the Chinese market to improve process robustness and reduce energy consumption in textile applications.
“Novozymes has been in China for more than 20 years, working closely with local companies and universities to develop technologies that reduce CO2 emissions and the use of harsh chemicals. We firmly believe it is in the society’s best interest that intellectual property rights are respected, as this maintains the necessary incentive to invest in tomorrow’s innovations,” adds Sara Dai.
Novozymes opened its office in Beijing in 1995 and today has more than 1,000 employees across 6 sites in China, where the company operates both research & development, production, sales, marketing and other support functions. Novozymes’ main businesses in China are in household care, textile, waste water treatment, food and beverage, agriculture and bioenergy.
Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet’s resources and helping build better lives. As the world’s largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future.
We call it Rethink Tomorrow.
NASDAQ OMX: NZYM-B ● 6,500 employees ● DKK 14,5 billion turnover ● 30+ industries ● 700+ products